Sana Biotechnology (SANA) Liabilities and Shareholders Equity (2020 - 2026)

Sana Biotechnology has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $373.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 16.14% year-over-year to $373.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 25.28% YoY) and the FY2025 annual result came in at $416.9 million, down 16.79% from the prior year.
• Liabilities and Shareholders Equity slipped to $373.6 million in Q1 2026 per SANA's latest filing, from $416.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.0 billion in Q1 2022 and troughed at $361.6 million in Q2 2025.
• A 5-year average of $634.3 million and a median of $618.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity slipped 8.78% in 2024, then plunged 41.54% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $822.7 million in 2022, then tumbled by 31.29% to $565.3 million in 2023, then fell by 11.37% to $501.0 million in 2024, then decreased by 16.79% to $416.9 million in 2025, then retreated by 10.39% to $373.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $373.6 million, $416.9 million, and $435.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.